[1] 中华医学会结核病学分会.抗结核药所致药物性肝损伤诊断与处理专家建议. 中华结核和呼吸杂志,2013,36: 732-736.
[2] Chave TA,Mortimer NJ, Sladden MJ,et al.Toxic epidermal necrolysis:current evidence,practical management and future directions.Br J Dermatol, 2005,153:241-253.
[3] 王庆枫,陈红梅.抗结核药物不良反应及其处理.中国临床医生志,2009.37: 18-19.
[4] Bjomsson E. The natural history of drug-induced liver injury.Semin Liver Dis, 2009, 29:357-363.
[5] Rangnekar AS, Fontana RJ. An update on drug induced liver injury. Minerva Gastroenterol Dietol, 2011, 57: 213-229.
[6] Abe R.Immunological response in Stevens-Johnson syndrome and toxic epidermal neerolysis.J Dermatol,2015,42:42-48.
[7] Saeed HN.Chndosh J.Immunologic mediators in Stevens-Johnson syndrome and toxic epidermal necrolysis.SeminOphthahnol,2016,31: 85-90.
[8] Choonhakarn C,Limpawattana P,Chaowattanapanit S.Clinical profiles and treatment outcomes of systemic corticosteroids for toxic epidermal necrolysis:a retrospective study.JDermatol,2016,43: 156-161.
[9] Jagadeesan S, Sobhanakumari K, Sadanandan SM, et al. Low dose intravenous immunoglobulins and steroids in toxic epidermal necrolysis: a prospective comparative open-labelled study of 36 cases.Indian J Dermatol Venereol Leprol,2013, 79: 506-511.
[10] Kardaun SH, Jonkman MF. Dexamethasone pulse therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis.ActaDerm Venereol,2007,87: 144-148.
[11] Yang Y, Zhang CK. Advance of intravenous immunoglobulin in pediatric treatment,Med Recapitulate,20IO,16:2200-2203.
[12] 中华医学会结核病学分会. 抗结核药所致药物性肝损伤诊断与处理专家建议. 中华结核和呼吸杂志,2013,36: 732-736. |
